Sort
46,585 grants matching “heart failure”
Cardio-Renal Effects of Torsemide vs. Furosemide: A TRANSFORM-HF Mechanistic Sub-Study
$799,302Jeffrey M Testani · Yale University · R01 · FY2020 · HL
Improving CBF through direct control of CSF pulsations
$799,298Mark Gregory Luciano · Cleveland Clinic Lerner Com-Cwru · R01 · FY2009 · NS
Novel Biomarkers to Predict Readmission in Pediatric and Adult Heart Surgery
$799,293Jeremiah R Brown · Dartmouth College · R01 · FY2015 · HL
Prospective Investigation of Cirrhotic Cardiomyopathy in Humans
$799,287Manhal Jaber Izzy · Vanderbilt University Medical Center · R01 · FY2025 · HL
Genetic Engineering of Vein Bypass Grafts in Vascular and Cardiovascular Surgery
$799,279Frank W Logerfo · Beth Israel Deaconess Medical Center · R01 · FY2019 · HL
Genetic Engineering of Vein Bypass Grafts in Vascular and Cardiovascular Surgery
$799,279Frank W Logerfo · Beth Israel Deaconess Medical Center · R01 · FY2020 · HL
Genetic Engineering of Vein Bypass Grafts in Vascular and Cardiovascular Surgery
$799,279Frank W Logerfo · Beth Israel Deaconess Medical Center · R01 · FY2021 · HL
Myocardial Vulnerability to Ischemia-Induced Dysfunction and Heart Failure: The Impact of HIV/SIV, ART, and Targeted Immunotherapy
$799,089Matthew Joel Feinstein · Northwestern University At Chicago · R01 · FY2020 · HL
Prognostic Significance of microRNA Expression in Children with Cardiomyopathy
$799,064Steven Edward Lipshultz · State University Of New York At Buffalo · R01 · FY2021 · HL
Leveraging Machine Learning Approaches to Understand Mechanisms of Exposure Therapy in Real-World Settings
$798,987Jennie M Kuckertz · Mclean Hospital · R01 · FY2024 · MH
Deacetylase-Dependent Control of Diastolic Dysfunction and HFpEF
$798,875Timothy McKinsey · University Of Colorado Denver · R01 · FY2019 · HL
Network Medicine and Systems Pharmacology to Advance Precision Medicine in Combined Pulmonary Hypertension
$798,826Evan L Brittain · Vanderbilt University Medical Center · R01 · FY2022 · HL
Antecedents of Impaired Brain Development in Fetuses with Heart Disease
$798,813Catherine Limperopoulos · Children'S Research Institute · R01 · FY2016 · HL
Mechanistic Insights to A Translatable Therapy for Acute Reperfused Hemorrhagic Myocardial Infarctions
$798,558Rohan Dharmakumar · Cedars-Sinai Medical Center · R01 · FY2021 · HL
FHFs and Cardiac Electrophysiology
$798,465Glenn I Fishman · New York University School Of Medicine · R01 · FY2020 · HL
Predicting Patient Instability Noninvasively for Nursing Care â Three (PPINNC-3)
$798,419Salah S Al-Zaiti · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · NR
TrAstuzumab Cardiomyopathy Therapeutic Intervention with Carvedilol (TACTIC) Trial
$798,417Joerg Herrmann · Mayo Clinic Rochester · R01 · FY2023 · CA
L-type channel trafficking and modulation in heart
$798,406Henry M Colecraft · Columbia University Health Sciences · R01 · FY2024 · HL
Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier
$798,351David Richard Light · Illexcor Therapeutics, Llc · R44 · FY2025 · HL
IMMUNOPATHOGENESIS OF CHRONIC GRAFT REJECTION
$798,266Harvard University (Medical School) · P01 · FY2000 · AI
Pericyte contribution to capillary remodeling in pulmonary arterial hypertension
$798,079Ke Yuan · Boston Children'S Hospital · R01 · FY2025 · HL
Stream Dx: accurate and efficient, point-of-care uroflometry for improved diagnosis, monitoring, and post-treatment evaluation of LUTS
$798,054Scott Bradford McClellan · Stream Dx, Inc. · R44 · FY2017 · DK
AAV-Exosomes: Escaping Neutralizing Antibody and Enhancing Delivery
$798,024Susmita Sahoo · Icahn School Of Medicine At Mount Sinai · R01 · FY2021 · HL
Identification and application of regulatory elements for heart regeneration
$797,975Kenneth D Poss · Duke University · R01 · FY2017 · HL
HIV, Cocaine &Regional Left Ventricular Dysfunction
$797,962Johns Hopkins University · R01 · FY2005 · DA